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Background: Discovery and validation of new antibody tractable targets is critical for the development of new antibody
therapeutics to address unmet needs in oncology.
Methods: A highly invasive clonal variant of the MDA-MB-435S cell line was used to generate monoclonal antibodies (MAbs), which
were screened for anti-invasive activity against aggressive cancer cells in vitro. The molecular target of selected inhibitory MAb 9E1 was
identified using immunoprecipitation/liquid chromatography-tandemmass spectrometry. The potential anti-tumour effects of MAb 9E1
were investigated in vitro together with immunohistochemical analysis of the 9E1 target antigen in normal and cancer tissues.
Results: MAb 9E1 significantly decreases invasion in pancreatic, lung squamous and breast cancer cells and silencing of its target
antigen, which was revealed as AnxA6, leads to markedly reduced invasive capacity of pancreatic and lung squamous cancer
in vitro. IHC using MAb 9E1 revealed that AnxA6 exhibits a high prevalence of membrane immunoreactivity across aggressive
tumour types with restricted expression observed in the majority of normal tissues. In pancreatic ductal adenocarcinoma, high
AnxA6 IHC score correlated with the presence of tumour budding at the invasive front of tumours (P¼ 0.082), the presence of
perineural invasion (P¼ o0.0001) and showed a weak correlation with reduced survival (P¼ 0.2242).
Conclusions: This study highlights the use of phenotypic hybridoma screening as an effective strategy to select a novel function-
blocking MAb, 9E1 with anti-cancer activity in vitro. Moreover, through characterisation of the 9E1 target antigen, AnxA6, our findings
support further investigation of AnxA6 as a potential candidate target for antibody-mediated inhibition of pancreatic cancer.
New antibody-tractable molecular targets are urgently required for
the development of effective bio-therapeutics for aggressive cancers
with urgent unmet needs. Cell surface proteins represent highly
attractive targets due to their accessibility; exploitation of candidate
targets exhibiting high differential cancer-specific expression holds
the potential to develop targeted antibodies such as antibody drug
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conjugates (ADCs) which are capable of selective drug delivery to
cancer cells without adversely affecting patients. Antibody drug
conjugates and dual targeting strategies using bi-specific antibodies
can improve clinical efficacy and overcome some of the limitations
of first-generation monoclonal antibody (MAb)-based
therapeutics.
Target agnostic approaches to identify functionally relevant
targets are gaining momentum for identifying novel candidate drug
targets, ultimately increasing the diversity of targets that will be
tested clinically. High through-put target-based screening and
omics approaches will not inform whether an antibody targeting
approach will have a direct impact on tumour cells. Phenotypic
hybridoma screening approach identifies candidate targets based
on the desired cancer functional phenotype, thus having the
potential to identify candidate proteins associated with a disease
relevant biological response and may also lead to delineation of
other disease targets/pathways. Functional screens have identified
antibodies that can induce apoptosis, inhibit cell proliferation or
internalise (reviewed by Gonzalez-Munoz et al, 2016). Such
candidates are considered to have a higher likelihood of success
in more advanced stages of drug development. We have previously
demonstrated that a phenotypic MAb screening approach followed
by mass-spectrometry identification of immunoprecipitated puta-
tive target antigens is an effective approach to identify candidate
protein targets functionally involved in cancer invasion in vitro
(O’Sullivan et al, 2014). Metastatic cancer is very challenging to
treat due to its systemic nature and resistance to therapies. Thus,
there is a continuing and urgent need to identify exploitable targets
directly involved in the invasive and metastatic phenotype, which
could have the potential to lead to the development of therapeutic
strategies to prevent or delay metastasis.
Herein we report the generation and isolation of a novel
function blocking MAb, designated 9E1, which was selected based
on its ability to significantly suppress the invasive phenotype
in vitro. This current study underscores the importance of such a
functional target discovery strategy through the successful mass
spectrometry identification of the functionally relevant molecular
target of MAb 9E1 and its characterisation as a potential anti-
cancer candidate protein target in a number of aggressive cancers.
MATERIALS AND METHODS
Cell lines. The MDA-MB-231, MDA-MB-468, MDA-MB-157,
BT-20, BT474, HS78T, MCF-7, SKBR-3, MDA-MB-361, T-47D,
NCI-H1299 and Lox-IVI cell lines were obtained from the
American Tissue Culture Collection (ATCC, Rockville, MD,
USA). The MiaPaCa-2 clone 3 pancreatic ductal adenocarcinoma
(PDAC) cell line and the DLKPA and DLKP-M squamous lung
carcinoma cell line were established in our laboratory (Clynes et al,
1992; McBride et al, 1998; Walsh et al, 2008).
Hybridoma generation. The immunogen chosen for MAb
generation was MDA-MB-435-SF10p4p, an invasive clonal variant
of the breast cell line, MDA-MB-435-S established in our
laboratory (Glynn et al, 2004). Prior to immunisations, a non-
enzymatic cell dissociation buffer was used to remove cells from
flasks (2 106 cells (50 ml volume)) following which cells were
washed and re-suspended in PBS plus an equal volume of
lipopeptide adjuvant, Pam3Cys-SKKKK (EMC microcollections,
Tubingen, Germany; L2000). Each mouse received a primary
immunisation, followed by four booster immunisations adminis-
tered at 3 weekly intervals. Three days prior to cell fusion mice
received one final immunisation. Immunisations were carried out
at the Royal College of Surgeons (RCSI) Biomedical Research
Facility, Beaumont Hospital, Dublin 9, Ireland; all immunisation
protocols were licensed by the Department of Health and Children,
Ireland.
Screening of hybridomas. Following fusion hybridomas were
screened directly for their ability to inhibit invasion in MDA-
MB435-SF cells and for their ability to show membrane
immunoreactivity on un-fixed, non-permeabilised cells. Briefly,
hybridomas were allowed to form large colonies and grow for at
least 10 days undisturbed. All resultant hybridomas were screened
initially, using a 96-well transwell Boyden chamber invasion assay
and a standard 24-well assay for subsequent screenings. Cells were
harvested at a concentration of 2.5 104 cellsml 1 in media (96-
well) or 1 106 cellsml 1 (24-well), and 50 ml (96-well) or 100 ml
(24 well) was added to each insert, along with an equal volume of
antibody or control hybridoma medium (no antibody).
Immunofluorescence studies. Immunofluoresence staining was
carried out as described previously with cells incubated overnight
with supernatants and a fluorescein isothicyanate-linked (FITC)
rabbit anti-mouse IgG secondary antibody (Dako, F0261
(O’Sullivan et al, 2014). Slides were viewed using a Nikon phase
contrast microscope fitted with an FITC filter.
Invasion assays. For all 96-well invasion assays and preliminary 24-
well assays stained inserts were designated as having decreased levels
of invasion or no effect on invasion relative to control hybridoma
medium inserts (no hybridoma supernatant, representing 100%
invasion) (three independent evaluators). For later screenings and
characterisation of MAb 9E1, the total number of invading cells was
determined by counting the number of cells per field in 10 random
fields at  200 magnification. The average number of cells per field
was then multiplied by a factor of 140 as described previously (Walsh
et al, 2008). (Note: due to inconsistency of invasion counts obtained
with both MDA-MB-435-SF and MDA-MB-435-SF Taxol 10p4P
cells, the extensively characterised cell lines, MiaPaCa-2 clone 3,
DLKP-M and MBA-MB-231 was chosen to carry out all further
MAb characterisation studies).
Motility assays. Motility assays were carried out in an identical
manner to 24-well invasion assays, as described above, with the
exception that the inserts were not coated in Matrigel.
Proliferation assays. Briefly, cells were harvested at 2 104
cellsml 1 in media and incubated at 37 1C, 5% CO2 overnight.
Following this, 100 ml of antibody was added to each well (control
wells, 100 ml hybridoma media added) and incubated at 37 1C, 5%
CO2 for 6–7 days, until the control wells had reached 80–90%
confluency. Assessment of cell survival in the presence of the
antibodies relative to control (no MAb – hybridoma control
medium only) was determined by the acid phosphatase assay.
Zymography. Zymography was carried out as described pre-
viously (O’Sullivan et al, 2014) with DLKP-M cells treated with
MAb 9E1 (50 mgml 1) or control cells (no MAb) for 24 h and
concentrated conditioned medium analysed. Zones of gelatinolytic
activity were detected as clear bands against a blue background.
Immunoprecipitation. Direct immunoprecipitation studies were
performed with MAb 9E1 and control mouse IgG (Sigma, I5381)
using protein L (P3351, Sigma, UK)/protein G agarose (Pierce,
22852). Purification, dialysis and concentration of MAb 9E1, pre-
clearing of lysates, immunoprecipitation of the antibody-antigen
complex, washing, elution and SDS–PAGE of 9E1 and mouse IgG
immunoprecipitates were carried out as previously described
(Larkin et al, 2005; O’Sullivan et al, 2014). Following gel
electrophoresis, gels were stained with Brilliant Blue Colloidal
Coomassie to visualise precipitated proteins. For validation of mass
spectrometry identifications, gels were probed with relevant
antibodies for western blotting (WB) analysis.
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Protein identification using liquid chromatography-tandem
mass spectrometry. Liquid chromatography-tandem mass spec-
trometry was performed on an Ultimate 3000 nanoLC system
(Dionex), interfaced to an LTQ Orbitrap XL (Thermo Fisher
Scientific). Preparation of samples was based on Shevchenko et al
(2006). Briefly, protein bands were excised from the Coomassie-
stained gel and destained. Samples were then dehydrated, digested
and peptides were extracted with acetonitrile/0.1% formic acid. A
5ml sample was loaded onto a trapping column, and the peptides
were eluted into a C18 PepMAP100 nanocolumn. Peptides were
then separated using mobile phase gradient. Liquid chromato-
graphy-tandem mass spectrometry data were acquired in data-
dependent acquisition mode controlled by Xcalibur 2.0.7 software
(Thermo Fisher Scientific).
Bioinformatic profiling of identified proteins. Database searches
were performed using TurboSEQUEST software (Bioworks
Browser version 3.3.1) (Thermo Fisher Scientific) using the human
subset from the SWISS-PROT database. The following filters were
applied: for charge state 1, XCorr41.5; for charge state 2,
XCorr42.5; for charge state 3, XCorr43.5.
RNA interference-mediated knockdown of AnxA6. Two pre-
designed siRNAs (Ambion) were chosen that target AnxA6
(Ambion, S1397 S1395), and transiently transfected into cells.
Each set of siRNA transfections carried out was accompanied with
a control (non-transfected) and a scrambled (SCR) transfection
(Ambion, 4390843). Solutions of siRNA at a final concentration of
30 nm were prepared in OptiMEM (Invitrogen). siRNA experi-
ments were set up using 2ml NeoFx (Ambion, AM4511) to
transfect 30Nm siRNA at a cell density of 3 105 per ml in a six-
well plate. Transfection medium was removed after 24 h and
replaced with fresh growth medium. A Kinesin-specific siRNA
(Ambion) was used a positive control in all knockdown
experiments to assess the efficiency of transfections.
The transfected cells were collected at 72 and 96 h for
immunoblotting and assayed for changes in invasion capacity at
24 h as described above.
Immunoblotting. SDS–PAGE, WB and ECL development was
carried out following extraction of whole cell lysates from relevant
cell lines and BCA protein concentration determination as
previously described (O’Sullivan et al, 2014). Enriched membrane
fractions of cell lines were isolated using the Calbiochem Native
membrane protein kit (444810), according to the manufacturer’s
guidelines. The following antibodies were used: MAb 9E1 super-
natants, AnxA6 (Abcam, ab5221,dilution 1 : 5000), Prohibitin
(Calbiochem, CP34, dilution, 1 : 800); 14-3-3 epsilon (Novus
Biologicals, NBPI 32695, 1 : 1000); beta-actin (Sigma, AS441,
dilution 1 : 10 000); a-Tubulin (Sigma, T5168, dilution 1 : 1000),
phospho and total ERK, MEK and p70SK6 (Cell Signalling,
4370, 4695, 2338, 9122, 9204 and 9202, dilution 1 : 1000 or
1 : 2000 (2338)).
Immunohistochemistry. Immunohistochemical staining of full
face 5mm sections and TMAs (lung cancer, LC72ai, US Biomax)
was performed using the Dako Autostainer Plus (Dako) according
to the manufacturer’s guidelines. Prior to staining, slides were
subjected to an antigen retrieval step consisting of a 20-min
incubation in Target Retrieval, ph 6, Dako S1699 for Ki-67 and a
15-min incubation in Target Retrival pH 9, Dako S2375 for 9E1.
Primary antibodies: MAb 9E1, (concentration: 10 mgml 1) and
MAb Ki67 (Clone MIB1, M7240, Dako, dilution 1 : 30) and
negative controls (primary antibody omitted, replaced by TBS)
were processed at the same time. Archival melanoma, breast,
PDAC, colon and renal tumours and control normal tissues were
obtained courtesy of the Departments of Pathology, St Vincents’
University Hospital (SVUH) Dublin and the Royal Victoria Eye
and Ear Hospital (RVEEH) Dublin. Ethical approval for IHC
analyses of tissues was obtained from the SVUH and RVEEH
ethics committees. Clinicopathological details were obtained from
patient records.
Immunohistochemistry scoring. MAb 9E1 immunoreactivity to
assess AnxA6 expression across normal and cancer tissues was
scored as absent, weak (faint cytoplasmic or nuclear staining of
scattered cells), moderate (intermediate or heterogenous mem-
brane staining in tumour cells/observed across tissue) or strong
(intense membrane staining in the vast majority of tumour cells/
observed across tissue). A semi-quantitative scoring system (based
on the staining intensity and the percentage of tumour cells
stained) was used to evaluate AnxA6 expression in the PDAC
cohort. Staining intensity was assigned as follows: (1þ , weak; 2þ ,
moderate; 3þ , intense; 4þ , very intense). The proportion of
tumour cells stained was scored as follows: (1¼ o5%; 2¼ 5–49%;
3¼ 50–69%; 4¼ 470% of tumour cells). AnxA6 expression was
assigned by combining the staining intensity scores and the
proportion of tumour cells stained. The minimum score when
summed (intensity and percentage) was 1 and the maximum score
was 8. Patients were stratified into two clinical score categories –
high AnxA6 expressing (overall score 5–8) or low AnxA6
expressing (overall score 1–4). Scoring was carried out by two
independent evaluators (AML, EMcA) blinded to specimen
and clinical detail and was also reviewed by a Consultant
pathologist (NS).
Statistical analysis. All data are presented as mean±standard
deviation (s.d.). Analysis of the difference of comparisons,
scrambled control siRNA versus siRNA treated mean invasion
and motility counts, adherence absorbance, and percentage
survival calculated, were performed using the student’s t-test
(two-tailed, unpaired with equal variance). A P-value of p0.05*,
p0.01**,p0.005*** was deemed statistically significant. Statistical
analysis was performed using Microsoft Excel and Prisim
Graphpad Software. All experiments were repeated a minimum
of three times; with the exception of initial hybridoma invasion
screenings (96-well and 24-well), preliminary immunofluoresence
studies and IHC analyses.
RESULTS
Isolation of anti-invasive hybridomas using functional screen-
ing. Five supernatants were chosen on the basis of a decrease in
invasion in MDA-MB-435 SF cells observed compared to
hybridoma control medium. Fifteen supernatants were selected
on the basis of their reactivity with MDA-MB-435 SF cells using
live cell immunofluorescence. Following expansion into 6-well
plates, and re-screening (invasion assays and immunofluores-
cence), hybridomas 4E5, 9E1, 102C, 1D2 and 104D were chosen
for further characterisation.
Selection of inhibitory MAb 9E1. MAbs 4E5 and 9E1 were
cloned by limiting dilution, the clone designated 24(6) arising from
the parental hybridoma, 9E1 was selected for further study as it
showed the most consistent anti-invasive effects and exhibited
‘punctate’-like membrane associated staining on non-permeabi-
lised cells (Figure 1) (note: MAb 9E1 clone 24(6) is referred to,
throughout this manuscript as MAb 9E1, its parental name). The
isotype of antibody 9E1 was revealed to be IgG1 (data not shown).
Quantification of MAb 9E1. Following isotype analysis which
revealed the isotype of antibody 9E1 as an IgG1, a panel of MAb
9E1 supernatants were then quantified using the Mouse IgG ELISA
Quantitation Set from Bethyl laboratories (USA) (Cat. No. E90-
131). These ranged from 50 mgml 1 to 103 mgml 1 IgG. An
excellent linear standard curve was obtained with MAb 9E1
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(concentration range 0–160 ngml 1) (data not shown). Dose
response studies on inhibitory effects of MAb 9E1 in MiaPaCa2-
clone 3 and DLKP-M cells demonstrated a dose response effect in
both cell lines over a range of concentrations (10–100 50 mgml 1)
(Figure 1C and Supplementary Figure 1B(i)). 50 mgml 1 of
antibody led to significant inhibition of invasion in both cell lines;
thus this concentration of MAb was used for all of the following
characterisation studies.
Immunofluorescence studies of MAb 9E1 in cancer cell lines.
Immunofluorescence staining to probe MAb 9E1 binding specifi-
city and cellular localisation of its target antigen revealed
‘punctate’-like membrane immunoreactivity across cell lines,
SKBR3, BT-474 (Figure 1D) DLKP-M, MiaPaCa-2 clone 3,
MDA-MB-231 and MDA-MB-435 cell lines (data not shown).
Taken together with WB reactivity observed in membrane
enriched fractions, these results strongly suggested that the putative
target antigen of selected inhibitory MAb 9E1 was a membrane
candidate protein.
Confirmation of specificity against cancer cell lines. Whole cell
lysates and membrane enriched fractions of breast cancer
(Supplementary Figure 1), colon, lung and PDAC cell lines (data
not shown) revealed that MAb 9E1 showed reactivity with an
approximately 65 kDa band across all cell lines (Supplementary
Figure 1).
MAb 9E1 impedes the invasive potential of aggressive cancer
types (breast, PDAC, squamous lung) in vitro. Further cancer
cell models were investigated to ascertain if antibody 9E1 could
also impede invasion in other aggressive cancers; the most
pronounced effects were observed in MiaPaCa-2 clone 3, a highly
invasive clonal population isolated from the parental MiaPaCa-2
PDAC cell line (mean inhibition level 79.6%) (Figure 1C and
Supplementary Figure 2) and DLKP-M squamous lung carcinoma
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Figure 1. The invasive potential of DLPK-M (A), MDA-MB-231 (B) and MiaPaCa-2 clone 3 (C) cells is significantly reduced in the presence of
50mgml 1 of 9E1 MAb, and to a lesser extent in the presence of 25mgml 1 of MAb indicating a dose response effect. Data plotted represent
the mean±standard deviation from a representative experiment. Statistics: *Pp0.05, **Pp0.01, compared to hybridoma medium control (no
MAb). Student’s t-test (two-tailed with equal variance, unpaired). Representative photomicrographs of invading cells are also shown (±Mab)
(Original magnification,  100; scale bar¼ 200mm). All experiments were performed a minimum of three times, and representative results are
presented. (D) ‘punctate’-like 9E1 immunoreactivity is observed in un-permeabilised SKBR3 and BT-474 cells.
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cells, a highly invasive clonal population isolated from the parental
DLKP cell line (mean inhibition level of 76.2%) (Figure 1A). The
inhibitory effects of MAb 9E1 in the other cancer cell lines were
not as marked but were significant: SKBR-3 (mean inhibition level
of 55.6%), MDA-MB-231 (mean inhibition level of 53.3%)
(Figure 1), LOX-IVI melanoma (mean inhibition level of 50%),
NCI-H1299 large cell lung (mean inhibition level of 34.5%)
(Supplementary Figure 3).
Identification of the MAb 9E1 target antigen. In order to identify
the putative target antigen of MAb 9E1 direct immunoprecipitation
followed by protein identification by mass-spectrometry was
performed. We choose three cell lines with abundant 9E1 target
expression: MiaPaCa-2 clone 3, NCI-H1299 and DLKPA. Bands were
revealed at approx. 175, 155, 65, 42 and 30kDa in all cell lines
(Figure 2A and B). Peptides from mass spectrometry identifications
were searched using the SWISS-PROT database. Bands 1 and 2, while
not apparent on gels with control mouse IgG immunoprecipitates,
were identified as mouse IgG. No definitive identification could be
obtained for band 4. A number of hits were obtained from the 30 kDa
reactive band (Supplementary Table 1); prohibitin, ADP/ATP
translocases 1, 2 and 3, 14-3-3 epsilon and 40S Ribosomal Proteins,
3 and S4 isoforms, Y1, Y2 and X. Prohibitin and 14-3-3 epsilon
proteins identifications were validated successfully with commercial
antibodies (data not shown). As WB analyses across a number of cell
lines had revealed only one reactive band at approximately 65 kDa, we
speculated that this band may represent the 9E1 target antigen. This
band was identified as AnxA6. As expected, when MiaPaCa 2 clone 3,
H12929 and DLKPA immunoprecipitates were probed with 9E1, only
the 65kDa band was identified. A representative MiaPaCa-2
immunoprecipitate probed with an AnxA6 specific antibody is shown
in Figure 2C, identifying the MAb 9E1 target antigen at approximately
65kDa, as AnxA6. Immunoblots were also run in parallel and probed
with MAb 9E1 which identified also the 65 kDa reactive band (data
not shown). A marked reduction in expression of the AnxA6 and 9E1
reactive bands were observed in AnxA6 siRNA transfected cells probed
with a commercial AnxA6 antibody and MAB 9E1, thus confirming
AnxA6 as the 9E1 MAb target antigen (Figures 2D, 3A and B).
MAb 9E1 effects on MMP-9 activity in MDA-MB-231 TNBC
cells. Zymographic analysis of conditioned medium from MDA-
MB-231 cells treated with antibody 9E1 revealed a reduction in
MMP-9 compared to conditioned medium from cells treated with
hybridoma medium only (control) (Supplementary Figure 1).
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Figure 2. Identification of the 9E1 target antigen. Representative SDS-PAGE gels showing (A) control mouse IgG and NCI-H1299; (B) MiaPaCa-2
clone 3 cells and control mouse IgG directly immunoprecipitated with MAb 9E1. Five bands were observed, at approx. 170, 155, 65, 42 and
30 kDa, which were not present in the control mouse IgG immunoprecipitates (IP). Each band was excised and run through an LCMS/LTQ mass
spectrometer for identification (Table 2). Experiments were carried on biological triplicate samples and on other cell lines (LOX-IVI, DLKPA) (results
not shown). Validation of the MAb target antigen as AnxA6 (65 kDa) is shown in (C): MiaPaCa-2 clone 3 IP probed with an AnxA6 specific
commercial antibody reveals a reactive band at 65 kDa. MiaPaCa-2 clone 3 and SKBR3 lysates also shown probed with AnxA6, (D) MiaPaCA-2
clone 3 cells transfected with AnxA6 siRNAs (a and b) probed with MAb 9E1 showing a marked reduction in expression of the 9E1 reactive band
relative to siRNA scrambled control. (loading control, alpha tubulin) (n¼ 3).
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These results indicated that 9E1 may possibly be eliciting its anti-
invasive effects through reduction of MMP-9 in MDA-MB-231
cells.
MAb 9E1 effects on the ERK-MEK signalling pathway in DLKP-
M cells. To further investigate the potential mechanism by which
MAb 9E1 may be reducing invasion we sought to examine the
effects of 9E1 antibody on the ERK-MEK/PK13S kinase signalling
pathways. The DLKP-M cell line was chosen to carry out this study
as MAb 9E1 treatment had significantly reduced invasion in a dose
responsive manner in this cell line and previous work in our
laboratory had implicated the ERK-MEK pathway in the invasive
phenotype of these cells. Inhibitory MAb 9E1 treatment resulted in
activation of ERK signalling (and MEK) (Supplementary Figure 4)
with possible reduction in activation of P70S6 kinase suggesting
that MAb 9E1 may be eliciting its anti-invasive effects, at least in
part, through modulation of these two pathways. These effects were
not observed upon treatment, carried out in parallel with
50 mgml 1 of an irrelevant IgG MAb.
RNA interference mediated knockdown of the 9E1 target
antigen, AnxA6 suppresses the invasive capacity of MiaPaCa-2
clone 3 and DLKP-M cells. Leading on from MAb 9E1’s
inhibitory effects on invasion, we then determined the effects of
siRNA-mediated knockdown to establish if AnxA6 is functionally
involved in cancer in vitro. Downregulation of AnxA6 significantly
reduced the invasive capacity of MiaPaCa-2 clone 3 and DLKP-M
cells (Figure 3). In agreement with MAb blocking experiments no
significant effect on proliferation or motility in either cell line was
observed following AnxA6 silencing, suggesting that the observed
reductions in invasion were not just reflecting altered cell
proliferation. Thus, AnxA6 is functionally involved in the invasive
phenotype of PDAC and lung squamous cancer in vitro. AnxA6
transfected cells were also probed with MAb 9E1; a marked
reduction in the 65 kda MAb reactive band was observed in lysates
transfected with siRNAs (Figure 2D (a and b)).
Immunohistochemistry analysis of AnxA6 using MAb 9E1.
AnxA6 (as indicated by MAb 9E1 moderate-strong immunor-
eactivity) shows a high prevalence of expression across colon,
PDAC, breast cancer and lung cancer sub-types with restrictive
expression across normal tissues (as indicated by very weak 9E1
immunoreactivity ino10% of tissue) and highly proliferating cells
and tissues (normal colon, skin and tonsil) (Table 1). Collectively
these results suggested that AnxA6, the 9E1 target antigen was
selective towards cancer tissues with minimal reactivity across
normal and highly proliferating cells and tissues.
Correlation of AnxA6 expression with clinicopathological
features in PDAC. Clinicopathological features of 57 patients
diagnosed with PDAC between 2007 and 2013 are presented in
Table 2. AnxA6 expression was observed in 57 of 57 PDAC
tumours. Tumours were stratified as either highly AnxA6
expressing (IHC score 3þ /4þ ) or weakly AnxA6 expressing
(IHC score 1þ /2þ ). A highly significant correlation was shown
between high AnxA6 IHC score (3þ /4þ ) and the presence of
perineural invasion (PNI) (P¼ o0.0001). High AnxA6 score also
correlated with tumours exhibiting tumour budding (vs no tumour
budding) (P¼ 0.0827).
No significant association with sex, age, tumour size, histological
grade, node status or presence of lymphovascular invasion was
shown.
Kaplan–Meier survival analysis of AnxA6 with outcome in
PDAC. Kaplan–Meier survival analysis carried out using
GraphPad PRISM revealed a clear trend towards high AnxA6
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Figure 3. Knockdown of AnxA6 reduces invasive capacity of MiaPaCa-2 clone 3 and DLKP-M cells. (A) Representative histogram showing reduced
invasive capacity of (A) MiaPaCa-2 clone 3 cells and (B) DLKP-M cells in a Boyden chamber assay following transfection with Anx-6 siRNAs, a and b.
Data plotted represent the mean±standard deviation of duplicate transwell inserts from a representative experiment. Statistics: *Pp0.05,
***Pp0.005, compared to scrambled siRNA control; Student’s t-test (two-tailed with equal variance, unpaired). A representative immunoblot is
shown indicating siRNA-mediated knockdown of AnxA6 in MiaPaCa-2 clone 3 and DLKP-M cells. Representative photomicrographs showing
invasion status of MiaPaCa-2 clone 3 cells following transfection are also shown. Original magnification, 10; scale bar¼ 200mm). All experiments
were performed a minimum of three times and representative results are presented.
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expression (IHC score 3þ /4þ ) being associated with a poorer
outcome in the 57 PDAC cohort (P¼ 0.2242); however, this failed
to reach significance. The study group, n¼ 57, was relatively small;
thus, significance may be achieved if expression is studied in a
larger patient cohort. Median survival of patients whose tumours
exhibited high AnxA6 (3þ /4þ ) expression was 632 days vs 998
days for patients whose tumours exhibited a lower AnxA6 IHC
score (1þ /2þ ) (Figure 4).
DISCUSSION
Phenotypic, target agnostic hybridoma screening is an attractive
strategy for novel antibody target discovery, with demonstrated
potential for clinical translation (Kinch et al, 2009; Dudley et al,
2014; Sandercock et al, 2015). Using such an approach candidate
MAb 9E1 was selected due to its potent inhibitory anti-invasive
effects across a number of aggressive cancer types (PDAC, lung,
melanoma and breast) and based on its ‘punctate’-like membrane
associated immunoreactivity on non-permeabilised cells (Figure 1).
MAb 9E1 reacted with a band at approximately 65 kDa across cell
lines. We thus speculated that this band represented the 9E1 target
antigen, which we subsequently confirmed with direct immuno-
precipitation studies. Liquid chromatography-tandem mass spec-
trometry identified the 65 kDa band as AnxA6 (Figure 3), which
we then validated by WB analysis. AnxA6 appears to have a
dichotomous role in cancer, displaying tumour suppressor and
tumour potentiating effects across various cancer types (Qi et al,
2015; Grewal et al, 2017). Here, siRNA-mediated knockdown of
AnxA6 significantly reduced the invasive capacity of both
MiaPaCa-2 clone 3 and DLKP-M cells, and thus implicates AnxA6
in PDAC and lung squamous cancer invasion in vitro. It is
noteworthy that probing of AnxA6 silenced cells demonstrated
that the 9E1 reactive band was markedly reduced providing further
evidence that AnxA6 was indeed the 9E1 molecular target. siRNA
knockdown studies have previously implicated AnxA6 in tumour
growth of gastric cancer cells and in breast cancer cell lines with
low levels of AnxA6 expression (Sakwe et al, 2011; Koumangoye
et al, 2013; Wang et al, 2013). Reduced expression of AnxA6
appears to inhibit motility and invasiveness of breast cancer cells,
supporting a tumour suppressor role for AnxA6 in breast cancer.
Perhaps AnxA6 is involved in proliferation in the context of its
tumour suppressor capacity and when acting as a pro–oncogene, it
is not directly contributing to proliferation, at least in the in vitro
setting. Obviously it may be involved in tumour growth in vivo as
cell signalling cross-talk between the tumour and the tumour
environment may impact on its mechanism of action. However,
our results clearly demonstrate that antibody-mediated targeted
blocking of AnxA6 can suppress the invasive phenotype in vitro.
AnxA6 has been shown to interact with Ras-ERK-MEK and/or
P13K pathways. siRNA-mediated suppression of AnxA6 was
previously shown to lead to enhanced EGF-induced Ras and
ERK activation in Hela cells (Grewal et al., 2005). Sakwe et al.
showed that AnxA6-dependent breast cancer adhesion and
motility were dependent on activation of the FAK-P13-AKT
pathway. We postulated therefore that mechanistically, MAB 9E1’s
blocking activity may be modulated via these signalling pathways.
As expected, we demonstrated that MAb 9E1 treatment leads to
Table 1. IHC analysis of AnxA6 expression in normal tissues and cancer tissues using MAb 9E1
Normal tissue AnxA6 expression as revealed by MAb 9E1 staining
Colon Weak positivity (non-proliferating cells)
Pancreas Weak-moderate positivity associated with islets
Gastric epithelium Weak/moderate positivity, isolated areas (1þ /2þ )
Breast Weak positivity isolated areas (1þ ) (o10% of tissue)
Lung Negative
Oesophagus Non-specific staining
Duodenum Weak positivity
Liver Negative
Tonsil Staining in areas surrounding germinal centres (non-proliferating cells, no staining in Ki-
67-positive cells)
Kidney Weak/moderate (1þ /2þ ) positivity in some tubules
Cervix Negative
Cancer AnxA6 expression as revealed by MAb 9E1 staining
PDAC 57/57 (100%)
Colon adenocarcinoma KRAS wt 5/5 (100%)
Colon adenocarcinoma KRAS mt 5/5 (100%)
Breast, HER-2 positive 56/70 (80%)
Breast, TNBC 6/6 (100%)
Lung adenocarcinoma 7/9 (77.8%)
Lung large cell 6/8 (75%)
Lung squamous 22/27 (81.5%)
Lung small cell differentiated 3/5 (60%)
Lung complexed small cell and squamous cell carcinoma 4/5 (80%)
Melanoma 2/2 (100%)
Renal carcinoma 2/2 (100%)
Abbreviations: AnxA6¼ annexin a6; MAb¼monoclonal antibody; PDAC¼pancreatic adenocarcinoma.
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activation of phospho-ERK while at the same time leads to possible
reduction in P70S6K activation. Interestingly immunoprecipita-
tion/mass spectrometry did identify the scaffold protein, prohibitin
(PHB) as an interacting protein of AnxA6 in this study. PHB forms
a signalling complex with CRAF at the cell surface to regulate
MEK-ERK activation in PDAC (Luan et al, 2014). We also
demonstrated that MAb 9E1 treatment leads to reduction in
MMP-9 activity in MDA-MB-231 cells. These results suggest that
perhaps MAb 9E1 (following binding to AnxA6) is exerting its
anti-invasive effects, in part, through modulation of the ERK
signalling axis involving MMP-9. ERK signalling has been shown
to modulate MMP-9 activity in MDA-MB-231 invasion (Moulik
et al, 2014). Future work is planned to eluciadate 9E1’s mechanism
of action following binding to its target antigen, AnxA6. Using
MAb 9E1 we demonstrated that AnxA6 is highly expressed in a
number of aggressive cancers (Table 1) namely, PDAC, lung
squamous, colon adenocarcinoma, TNBC and HER-2 positive
breast cancers. A concern for any potential therapeutic antibody
targeting approach is the potential for off-tumour toxicities due to
expression of the candidate protein in normal tissues. Restricted
AnxA6 expression as indicated by weak/negligible 9E1 immunor-
eactivity was observed in the vast majority of normal tissues
representing vital organs studied (Table 1 and Figure 4).
Membrane AnxA6 immunoreactivity was observed in islet cells
in pancreas and in isolated cells in duodenum and gastric
epithelium and in some kidney ducts; however, in all cases weak
to moderate staining only was revealed and was not homogenously
observed across tissues. In addition to differential and selective
expression, minimal expression of the potential ADC molecular
target in highly proliferating cells is essential. Our studies
demonstrate that AnxA6 expression is not associated with
highly proliferating, Ki-67 positive cells and would fulfil this
particular criteria.
A potential molecular target should be abundantly and
selectively expressed on the cell surface. Our preliminary experi-
ments indicated that the 9E1 target antigen was observed in
membrane enriched fractions across tumour cell lines and we
observed ‘punctate’-type 9E1 immunoreactivity, suggesting a
potential association with vesicular structures, perhaps exosomes.
Given the fact that MAb 9E1 markedly reduces the invasive
capacity of tumour cells, it was likely thus that the putative
molecular target of MAb 9E1 was likely to be a cell surface protein.
Indeed, AnxA6 has been implicated as a multifunctional scaffold
protein, recruiting signalling proteins, modulating cholesterol and
membrane transport and influencing actin dynamics, all of which
require AnxA6 to be localised at either the plasma membrane or
endocytic compartments (Pons et al, 2001; Koese et al, 2013;
Koumangoye et al, 2013). AnxA6 has also been observed in
membrane protrusions of breast cancer cells. Interestingly a recent
study by Leca et al. has identified a complex of AnxA6/LRP1/TSP-
1 in cancer-associated fibroblasts (CAFs) in PDAC and demon-
strated that uptake of CAF-derived AnxA6 is directly linked to
PDAC aggressiveness (Leca et al, 2016). In the context of
investigating AnxA6 as a possible candidate for targeting using
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Figure 4. IHC analysis with MAb 9E1 demonstrates that AnxA6 shows limited expression in normal and highly proliferating tissues (A) with
strong membrane AnxA6 expression observed in colon adenocarcinoma (B) and PDAC (C). High AnxA6 expression was significantly associated
with the presence of PNI (P¼0.0001) and with tumours exhibiting tumour budding (P¼ 0.0082) in PDAC and showed a weak correlation with
outcome (P¼ 0.2242) in this 57 PDAC cohort.
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an ADC approach, we are currently assessing if this Mab can
induce internalisation of the antibody antigen complex upon
binding of AnxA6 at the cell surface, which is critical for any
potential ADC targeting approach. We observed AnxA6 immu-
noreactivity in PDAC tumour stroma in approximately 50% of
tumours. There is emerging evidence that LRP-1 is involved in
tumour adhesion and invasion via modulation of ERK and JNK
pathways. Although we did not identify LRP-1 (or TSP-1) as an
interacting partner of AnxA6 here, it is not unreasonable to
speculate that AnxA6 may be mediating effects on invasion
through interaction with LRP-1 and subsequent activation of ERK
signalling. Interestingly in the context of exploring AnxA6 as a
potential antibody target, AnxA6 has been shown to be involved in
the regulation of IL-2 signalling and T-cell plasma membrane
organisation (Cornely et al, 2016). T cells and immune checkpoints
have become the focus of numerous efforts to therapeutically
modulate anti-tumour immune response.
To our knowledge, we show for the first time evidence of
membrane AnxA6 expression in both colon adenocarcinoma and
PDAC (Figure 4B and C), indicating that AnxA6 is specifically and
abundantly expressed in both cancers. As we had demonstrated,
using MAb 9E1, that targeting AnxA6 can significantly impede
PDAC invasion, we hypothesised that AnxA6 may be involved in
PDAC tumourgenesis, at least in the early invasive stages of the
tumour, we then analysed AnxA6 expression in 57 PDAC tumours.
Pancreatic adenocarcinoma (PDAC) is a highly aggressive and
chemoresistant tumour and is virtually incurable with current
treatment modalities available. The observation of weak AnxA6
expression associated with islet cells in normal pancreas is interesting;
B cells in islets have been demonstrated to express stem cell markers,
LGR5 and Nanog both of which are involved in PDAC tumour
development (Amsterdam et al, 2013). Strong pERK expression has
been reported in islet cells. In early stages of PDAC (Amsterdam
et al, 2013), elevated ERK activity, resulting from mutation of KRAS,
has been shown to be a common event in PDAC.
AnxA6 was expressed in 100% of PDAC tumours with intense
membrane immunoreactivity observed in 36 out of 57 (63%) of
tumours (Table 2). Higher AnxA6 expression was significantly
associated with the presence of PNI (Po0.0001). Perineural invasion
(PNI) is a hallmark of PDAC and a strong predictor of poor prognosis.
No significant association between high AnxA6 expression and lymph
node involvement was revealed despite the highly significant
association with PNI. Tumour budding, small groups of individual
tumour cells in the stroma near the invasive front of the tumour, is
also an indicator of adverse outcome in PDAC. A greater proportion
of tumours where tumour budding was present showed high AnxA6
immunoreactivity compared to tumours where tumour budding was
absent (P¼ 0.0827) (Figure 4). These results suggested that AnxA6 is
likely to be involved at the early stages of PDAC progression (local
invasion). Furthermore, PDAC tumours with higher AnxA6 expres-
sion showed a clear trend towards a poorer outcome vs those tumours
with lower expression of AnxA6 (P¼ 0.2242); however, this failed to
reach significance.
In conclusion, our study highlights the use of phenotypic
hybridoma screening in the isolation and development of a novel
function blocking, inhibitory MAb, 9E1 with anti-cancer activity
and identified its target antigen, AnxA6 as a functionally relevant
target molecule. Using MAb 9E1, we have shown that AnxA6
shows a tumour restricted tissue expression profile; it is abundantly
expressed in a number of aggressive cancers with limited
expression across the vast majority of normal tissues. Moreover,
we have demonstrated that strong AnxA6 expression is associated
with adverse clinicopathological features and outcome in PDAC.
The potent anti-invasive effects of MAb 9E1 warrant further
Table 2. IHC analysis of AnxA6 expression in PDAC (N¼57) using MAb 9E1 and correlation with clinicopathological features
AnxA6
Clinicopathological feature
No. of positive
tumours
High immunoreactivity
(IHC score 4–8)
Low immunoreactivity
(IHC score 1–4) P-value
Overall 57 36 (63.1%) 21 (36.84%)
Sex
Male 22/36 (61.1%) 14/21 (66.66%) 0.7452
Female 14/36 (38.8%) 7/21 (33.33%)
Age
o65 19/36 (52.77%) 12/21 (57.1%) 0.9022
465 17/36 (47.3%) 9/21 (42.85%)
Tumour size
o4 cm 29/36 (80.55%) 15/21 (71.4%) 0.4332
4 4 cm 7/36 (19.44%) 5/21 (23.8%)
Histological grade
Grade I 3/36 (8.33%) 2/21 (9.52%) 0.3624
Grade II 25/36 (69.44%) 12/21 (57.1%)
Grade III 8/36 (22.22%) 7/21 (33.33%)
Node status
N0 10/36 (27.77%) 8/21 (38%) 0.4234
N1 26/36 (72.2%) 13/21 (61.9%)
Lymphovascular invasion (LVI)
Present 24/36 (66.66%) 13/21 (61.9%) 0.7223
Absent 12/36 (33.33%) 8/21 (38%)
Perineural invasion (PNI)
Present 28/36 (77.7%) 2/21 (9.52%) o 0.0001
Absent 8/36 (22.22%) 19/21 (90.4%)
Tumour budding
Present (n¼13) 11/13 (84.6%) 2/13 (15.4%) 0.0827
Absent (n¼ 20) 11/20 (55%) 9/20 (45%)
Unknown (n¼ 24) — —
Abbreviations: AnxA6¼ annexin a6; IHC¼ immunohistochemistry; MAb¼monoclonal antibody; PDAC¼ pancreatic adenocarcinoma. Bold values indicate statistical significance.
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studies to fully elucidate its mechanism of action in vitro, and
suggest that such an antibody targeting approach could be
potentially investigated in vivo, in pre-clinical studies. Taken
together, our findings suggest that AnxA6 may represent a
potential candidate protein for exploration of antibody-mediated
targeting for PDAC (and potentially other aggressive cancer types).
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